Diabetes Mellitus Type 1 Clinical Trial
This prospective, non-randomized, non-controlled, interventional study will determine whether the Roche automated bolus caclulator (ABC) reduces post-meal hyperglycemia better than the competitor's ABC without causing significant hypoglycemia.
| Status | Completed |
| Enrollment | 24 |
| Est. completion date | December 2009 |
| Est. primary completion date | December 2009 |
| Accepts healthy volunteers | |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Subjects >/= 18 years at screening - Type 1 diabetics currently using an insulin pump for management of their diabetes and have been on a pump for at least at least 6 months prior to the screening visit - Subjects have to use a fast acting analog insulin - HbA1c = 9% (measured with DCA 2000) - Willing to perform periods of intensive blood glucose (BG) monitoring for up to 21 days prior to the study (~10 tests per day) with skipped meals and testmeals - Willing to use the 3 different bolus calculators during the course of the study - Willing to undergo planned hyperglycemia - Willing to perform high frequency BG monitoring (> 20 / day) during the experiment Exclusion Criteria: - Type 2 Diabetes - Manifest severe late complications of diabetes (e.g. severe macro- or microangiopathy, severe neuropathy, severe retinopathy and/or severe nephropathy) - Current addiction to alcohol or substances of abuse - Pregnant or lactating women - Any known life-threatening disease |
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Hoffmann-La Roche |
Germany,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | To compare the difference between the self-monitoring blood glucose (SMBG) value achieved at 6 hours after meals with induced post-prandial hyperglycemia and the mean target value of 110 mg/dL. Target post-prandial range is 80-140 mg/dL. | 6 hours after meal | No | |
| Secondary | To compare the absolute difference between the SMBG value and the target value between the calculators | 6 hours after meal | No | |
| Secondary | To compare theto compare the relative difference (multiplied by 100) between the SMBG value and the target value between the calculators | 6 hours after meal | No | |
| Secondary | To compare the absolute relative difference (RAD, multiplied by 100) between the SMBG value and the target value between the calculators | 6 hours after meal | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01508065 -
Measuring and Monitoring Blood Glucose Levels Utilizing Non-invasive Blood Glucose Monitoring Device
|
||
| Completed |
NCT01788033 -
Effects of XOMA 052 on Insulin Production in Type 1 Diabetes
|
Phase 2 | |
| Active, not recruiting |
NCT01271517 -
Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis
|
Phase 4 | |
| Recruiting |
NCT01800734 -
Mixed Meal Test in Type 1 Diabetes: Optimization of Artificial Pancreas-Pilot Study
|
Phase 4 | |
| Recruiting |
NCT06088615 -
Feasibility of Non-invasive Glucose Monitoring by Using Photothermal Deflectometry
|
||
| Completed |
NCT02127047 -
Effects of Exercise and Inhibition of Dipeptidyl Peptidase-4 on Insulin Secretion in Subjects With Type 1 Diabetes
|
Phase 2 | |
| Completed |
NCT01689090 -
Diameter Changes of Retinal Vessels During Hypoxia
|
N/A | |
| Completed |
NCT00006505 -
Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression
|
Phase 2 | |
| Not yet recruiting |
NCT06217302 -
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
|
Phase 3 | |
| Recruiting |
NCT02750111 -
Continuous Glucose Monitoring During Intecorse in Young Adults With Type 1 Diabetes
|
N/A | |
| Recruiting |
NCT02545062 -
MoCa Test for the Early Detection of Mild Cognitive Impairment During Annual Assessment of Young Adults With Diabetes and in a Control Group Without Diabetes
|
N/A | |
| Completed |
NCT02146651 -
A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes
|
Phase 2 | |
| Completed |
NCT02538120 -
Assessment of the Neurovascular Microcirculatory Response in Diabetes Type 1 Patients
|
N/A | |
| Completed |
NCT02403375 -
Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes
|
N/A | |
| Terminated |
NCT00896610 -
Natural History of Autoimmune Diabetes and Its Complications
|
||
| Terminated |
NCT02701257 -
The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas
|
N/A | |
| Completed |
NCT02094534 -
A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics
|
Phase 2 | |
| Completed |
NCT01334151 -
Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes
|
Phase 1 | |
| Active, not recruiting |
NCT02624804 -
A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes
|
Phase 1 | |
| Completed |
NCT02465411 -
Long Term CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin Injections
|
N/A |